Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALPG | P10696 | 2/20 | 0.34 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.34 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11930749 | 0.85 | FPR2 (0.42) | FPR2KDM4EALDH1A1OPRD1OPRK1 | |
| SCHEMBL21247638 | 0.85 | FPR2 (0.40) | FPR2KDM4EALDH1A1OPRD1OPRK1 | |
| SCHEMBL11930753 | 0.82 | FPR2 (0.40) | FPR2KDM4EALDH1A1OPRD1OPRK1 | |
| SCHEMBL13263679 | 0.82 | ALPG (0.49) | FPR2KDM4EALDH1A1HDAC6ALPG | |
| SCHEMBL16607258 | 0.81 | FPR2 (0.43) | FPR2ALPGPLAAALPL | |
| SCHEMBL13382073 | 0.81 | FPR2 (0.40) | FPR2KDM4EALDH1A1OPRD1OPRK1 | |
| SCHEMBL20724674 | 0.80 | FPR2 (0.45) | FPR2ALDH1A1ALPGPLAAALPL | |
| SCHEMBL18079522 | 0.77 | FPR2 (0.37) | FPR2KDM4EALDH1A1OPRD1OPRK1 | |
| SCHEMBL13341514 | 0.77 | CA2 (0.41) | FPR2 | |
| SCHEMBL28455345 | 0.77 | FPR2 (0.44) | FPR2KDM4EALDH1A1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712485-B2 | Triazine based radiopharmaceuticals and radioimaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20210338850-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338850-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | PSMA2, PSMA5, PSMA1 | FPR2 2312/4885KDM4E 2245/4885ALDH1A1 2027/4885 |
| US-11712485-B2 | Triazine based radiopharmaceuticals and radioimaging agents | PSMA2, PSMA5, PSMA1 | FPR2 2312/4885KDM4E 2245/4885ALDH1A1 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.